Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Data on FASLODEX Injection presented at symposium
January 13th, 2005
Important new data from two phase II studies evaluating FASLODEX (fulvestrant) Injection as treatment for postmenopausal women with advanced breast cancer, who have experienced disease progression on aromatase inhibitor therapy, were presented at the San Antonio Breast Cancer Symposium (SABCS). The first of the two studies, conducted by Dr. L. Perey from the Swiss Group for Clinical Cancer Research (SAKK) in Bern, Switzerland, evaluated treatment with FASLODEX in 67 postmenopausal women with advanced breast cancer who had previously responded to aromatase inhibitor treatment but had experienced disease progression. In this study, 19 patients (28%) experienced a partial...
Source: Women's Health Weekly (2005-01-13)
|
